Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AVPR1A | P37288 | 19/20 | 0.67 |
| ▸ | AVPR2 | P30518 | 5/20 | 0.67 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2542009 | 1.00 | AVPR1A (0.67) | AVPR1AAVPR2KCNH2 | |
| SCHEMBL2546578 | 1.00 | AVPR1A (0.67) | AVPR1AAVPR2KCNH2 | |
| SCHEMBL2547667 | 0.91 | AVPR1A (0.56) | AVPR1AAVPR2KCNH2 | |
| SCHEMBL2545574 | 0.91 | AVPR1A (0.68) | AVPR1AAVPR2KCNH2 | |
| SCHEMBL2545576 | 0.91 | AVPR1A (0.68) | AVPR1AAVPR2KCNH2 | |
| SCHEMBL16774879 | 0.91 | AVPR1A (0.56) | AVPR1AAVPR2KCNH2 | |
| SCHEMBL2542067 | 0.89 | AVPR1A (0.54) | AVPR1AAVPR2KCNH2 | |
| SCHEMBL2542069 | 0.89 | AVPR1A (0.54) | AVPR1AAVPR2KCNH2 | |
| SCHEMBL2539886 | 0.89 | AVPR1A (0.60) | AVPR1AAVPR2KCNH2 | |
| SCHEMBL2539890 | 0.89 | AVPR1A (0.60) | AVPR1AAVPR2KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2560975-B1 | HETEROARYL-CYCLOHEXYL-TETRAAZABENZO[E]AZULENES AS VASOPRESSIN V1A RECEPTOR ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2015-06-17 | — | — | EP | disclosed |
| US-8492376-B2 | Heteroaryl-cyclohexyl-tetraazabenzo[e]azulenes | HOFFMANN-LA ROCHE INC. (US) | 2013-07-23 | — | — | US | disclosed |
| US-8492376-B2 | Heteroaryl-cyclohexyl-tetraazabenzo[e]azulenes | HOFFMANN-LA ROCHE INC. (US) | 2013-07-23 | — | — | US | disclosed |
| US-20110263578-A1 | HETEROARYL-CYCLOHEXYL-TETRAAZABENZO[E]AZULENES | HOFFMANN-LA ROCHE, INC. | 2011-10-27 | — | — | US | disclosed |
| US-20110263578-A1 | HETEROARYL-CYCLOHEXYL-TETRAAZABENZO[E]AZULENES | HOFFMANN-LA ROCHE, INC. | 2011-10-27 | — | — | US | disclosed |
| US-20110263578-A1 | HETEROARYL-CYCLOHEXYL-TETRAAZABENZO[E]AZULENES | HOFFMANN-LA ROCHE, INC. | 2011-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110263578-A1 | HETEROARYL-CYCLOHEXYL-TETRAAZABENZO[E]AZULENES | AVPR1A, AVPR1B, OXTR | AVPR1A 1/4885AVPR2 4/4885KCNH2 778/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.